Sustained Low-Dose Tirzepatide Linked to 5.5% Weight Loss in EHR Cohort

{"The observational study in Biology Methods & Protocols extracted records meeting criteria of at least three consecutive starter doses over six months. After propensity matching on age, sex, BMI and diabetes status, high-dose semaglutide users reached 12% loss while low-dose users reached 1.7%, confirming dose-response yet documenting clinically detectable effects at initiation levels.","Lower gastrointestinal adverse-event rates accompanied the modest losses, aligning with prior STEP and SURMOUNT trial gradients. However, the design cannot separate intentional microdosing from titration delays or supply constraints, and lacks randomization or standardized lifestyle controls present in the pivotal RCTs.","Cardiometabolic benefit thresholds (blood pressure, glycemic markers) were not reported, leaving open whether 2–5% loss suffices for hard outcomes. Real-world persistence data suggest many patients plateau on starter doses, prompting later escalation.","A pragmatic RCT comparing fixed low-dose versus standard titration, powered for both weight and side-effect endpoints at 18 months, is required to guide practice."}